IL17A and rheumatoid arthritis: Indeed, treating AIA with commercially available neutralising antibodies to IL-17 has been previously reported to reduce clinical symptoms of arthritis36 and neutrophil accumulation within the joint.37 It is important to note that Ab-IPL-IL-17 was as effective at halting disease progression and triggering resolution as the gold-standard current treatment for RA, infliximab (figure 5A,B) with a significant reduction in infiltrating neutrophils (figure 5C).